Paul Moore, Ph.D.Vice President, Immunology & Cell Biology at MacroGenics
Profile
25 years of experience working in biotech, coordinating efforts focused on the discovery and development of novel biologic based therapies. At MacroGenics, leads a research group dedicated to the discovery, preclinical development and clinical translational biology of antibody-based therapeutics including Fc-optimized mAbs and bispecifics for cancer or autoimmune disease through harnessing of the host immune system. Began biotechnology career at HGS, where directed genomic-based target discovery programs and the preclinical development of various protein and mAb-based therapeutics. Notably these efforts led to the discovery of BLyS as a B-cell survival factor providing the basis for the development of Benlysta for the treatment for lupus. Obtained PhD from University of Glasgow and performed post-doctoral work at the Roche Institute of Molecular Biology; co-authored over 70 peer-reviewed manuscripts and 40 issued US patents
Agenda Sessions
Multispecific, Multivalent Antibody-Based Molecules Engineered on the DART® and TRIDENT® Platforms
On DemandView SessionNew Approaches to Multispecific Antibody Treatment
12:30View Session